Borrower record · Q2 2026
BioXcel Therapeutics
As filed by 2 BDCs · period end 30 June 2026Filers label it: Pharmaceuticals (2)1 name variant under review
Two lenders report $12.5m of BioXcel Therapeutics at Q2 2026, marked at 86.4 cents. It is equity, not loans: no filer disclosed a spread on any tranche.
- Filed fair value
- $12.5m
- 7 funded positions
- Reporting lenders
- 2
- across 10 filed positions
- Aggregate mark
- 86.4c
- covers 50% of positions with a filed cost
- Maturities to
- 2027
- one date, 19 April 2027
- Periods on record
- 5
- first filed Q2 2025
How this total is counted
- Every figure above is the sum of 7 funded positions filed by 2 BDCs, each one cited below.
- Counted from the Q2 2026 filings imported for this build, the latest of them filed 20 August 2026. A schedule filed after that date is not in these figures and will appear when the property is rebuilt.
- 3 filed positions carry no positive fair value — unfunded or written off — and are outside every figure above.
- 1 filed name variant is under review against this borrower. Until it is resolved, anything filed under that name is counted nowhere on this page.
Capital structure
All 7 funded positions carry a filed seniority.
Maturity profile
4 of 7 funded positions dated2027
$12.2m
0.8 years to maturity, weighted by fair value across the 4 dated positions.
Credit flags
Pays in kind4 positions at 2 lenders carry a PIK component, the largest filed at 1,300bp, $12.2m of fair value.
Not in the filings
- No sector. 2 filers file the same industry string, shown above as filed, but it has not cleared the corroboration test.
- No spread, index or floor. No filer disclosed one for any tranche.
- No period-by-period totals across the 5 periods on record. A single filer is separable somewhere in that history — at a period only one of them reported, or in the difference between two — so the series would give up that filer's position.
- No maturity on 3 of 7 funded positions. Undated is left undated, not assumed.
Sign up for free
Who holds it, and where they mark it.
2 lenders hold the same credit and mark it differently. Behind the gate, one row each — for this borrower and for every other one on this site, free and with no limit on how many you read.
LenderPositionsFair valueMarkSpreadMaturityAccrual
- The spread between the highest and lowest lender mark
- Quarter-on-quarter movement across 5 periods
- Peer comparison against borrowers with the same lenders
- The 10-Q or 10-K behind every row, by accession number
Every filing behind this page
2 filers · Q2 2026| Filer | CIK | Form | Period | Filed | Accession |
|---|---|---|---|---|---|
| Oaktree Specialty Lending Corp (OCSL) | 0001414932 | 10-Q | 2026-06-30 | 2026-08-05 | 0001414932-26-000017 |
| Oaktree Strategic Credit Fund | 0001872371 | 10-Q | 2026-06-30 | 2026-08-12 | 0001872371-26-000013 |
Related borrowers
Same lenders